Objective-To explore the role of systemic inflammation in the regulation of adiponectin levels in patients with ischemic heart disease. Approach and Results-In a cross-sectional study of 575 subjects, serum adiponectin was compared between healthy subjects, patients with coronary artery disease with no/mild/severe heart failure (HF), and patients with nonischemic HF. Adiponectin expression and release from femoral, subcutaneous and thoracic adipose tissue was determined in 258 additional patients with coronary artery bypass grafting. Responsiveness of the various human adipose tissue depots to interleukin-6, tumor necrosis factor-α, and brain natriuretic peptide (BNP) was examined by using ex vivo models of human fat. The effects of inducible low-grade inflammation were tested by using the model of Salmonella typhi vaccine-induced inflammation in healthy individuals. In the cross-sectional study, HF strikingly increased adiponectin levels. Plasma BNP was the strongest predictor of circulating adiponectin and its release from all adipose tissue depots in patients with coronary artery bypass grafting, even in the absence of HF. Femoral AT was the depot with the least macrophages infiltration and the largest adipocyte cell size and the only responsive to systemic and ex vivo proinflammatory stimulation (effect reversible by BNP). Low-grade inflammation reduced circulating adiponectin levels, while circulating BNP remained unchanged. Conclusions-This study demonstrates the regional variability in the responsiveness of human adipose tissue to systemic inflammation and suggests that BNP (not systemic inflammation) is the main driver of circulating adiponectin in patients with advanced atherosclerosis even in the absence of HF. Any interpretation of circulating adiponectin as a biomarker should take into account the underlying disease state, background inflammation, and BNP levels. (Arterioscler Thromb Vasc Biol. 2014;34:2151-2159.)
A diponectin is abundantly secreted from adipose tissue (AT), and it plays a role in glucose metabolism and obesity-related insulin resistance. [1] [2] [3] In human atherosclerosis, adiponectin suppresses vascular oxidative stress and has an antiatherogenic potential. [4] [5] [6] However, the mechanisms controlling its biosynthesis in the various AT depots and determining its circulating levels are unclear, whereas its clinical value as a biomarker is controversial.
In prospective studies, increased serum adiponectin has been associated with lower risk of developing diabetes mellitus and cardiovascular disease (CVD). 7 However, the data about the predictive value of adiponectin in coronary artery disease (CAD) are conflicting [8] [9] [10] [11] [12] ; that is, in advanced disease states (eg, in ischemic heart failure [HF]), adiponectin flags poor prognosis independently of the underlying metabolic state. 2, 4, 13 Therefore, a better understanding of the mechanisms controlling adiponectin levels in different CVD states may allow its use as a clinical biomarker and may identify novel therapeutic targets in patients with advanced CVD.
The regulation of adiponectin biosynthesis is complex; in cultured adipocytes, proinflammatory cytokines down-regulate adiponectin (or ADIPOQ) gene expression, 14, 15 whereas severe inflammation in experimental animal models downregulates its expression and reduces circulating adiponectin levels. 16 In humans, however, atherosclerosis-related lowgrade inflammation has been associated with both increased 17 and decreased 11 plasma adiponectin, while there is also evidence that advanced, chronic inflammation may even increase adiponectin levels. 18, 19 These conflicting findings suggest that mechanisms related with the underlying disease state may override the regulatory role of inflammation on adiponectin biosynthesis in advanced CVD states. As such, stimulation of adiponectin synthesis in cultured adipocytes by brain natriuretic peptide (BNP) could explain the increased adiponectin levels in patients with HF despite the significant background inflammation, 20 although this link between BNP and adiponectin biosynthesis has never been demonstrated at the level of human AT.
In this study, we explore the interplay between systemic inflammation and BNP in the regulation of adiponectin expression and release from different human AT depots using ex vivo models of human AT. Using in vivo and ex vivo models of inflammation and a model of inducible low-grade inflammation, we comprehensively characterize the relationship between systemic inflammation and adiponectin levels in humans.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Impact of Left Ventricular Function and Circulating BNP on Adiponectin Expression/Release From AT of Patients With Ischemic Heart Disease
Study design is summarized in Figure 1 and patient demographics in the Table. In study arm 1, we observed that body mass index was inversely correlated with circulating adiponectin in healthy individuals ( Figure 2A ) and patients with CAD and preserved left ventricular ejection fraction ( Figure 2B ), but this association was lost in patients with established left ventricular impairment of ischemic or nonischemic pathogenesis ( Figure 2C ). Circulating adiponectin levels were not significantly different between patients with CAD with normal or mildly impaired left ventricular ejection fraction and healthy individuals ( Figure 2D ). However, there was a striking elevation of circulating adiponectin in the presence of ischemic or nonischemic HF as evidenced by impaired left ventricular ejection fraction ( Figure 2D ). Importantly, plasma levels of high-sensitivity C-reactive protein (hsCRP) were significantly elevated in the patients with CAD compared with healthy controls, and they were further increased in the presence of HF (Table) . Interestingly, the significant correlation observed between circulating adiponectin and flow-mediated dilatation, a marker of endothelial function, in the healthy population was weaker in patients with advanced atherosclerosis and preserved left ventricular ejection fraction, and it was lost in patients with ischemic or nonischemic HF ( Figure 2E -2H).
To explore the relationship between systemic inflammation and adiponectin levels in atherosclerosis, we focused on a more homogenous group of patients with CAD without evidence of HF, undergoing coronary artery bypass grafting (study arm 2). In this cohort, we searched for predictors of circulating adiponectin. In univariate analysis, there was a significant correlation between log(serum adiponectin) and age (r=0. 179 . Given that this model was built only with demographic/anthropometric characteristics of the participants, we then searched for additional biomarkers that could predict circulating adiponectin. We quantified plasma BNP, and we observed a significant association between log(plasma BNP) and log(serum adiponectin) (r=0.282, P<0.0001). When log(plasma BNP) was included into the multivariable model, it became clear that this was the strongest independent predictor of log(serum adiponectin) with (β [SE], 0.153 [0.05]; P=0.003), even in the absence of clinical HF. Importantly, circulating BNP was significantly associated with both the expression ( Figure 3A , and further supporting the notion that in human atherosclerosis, circulating BNP (rather than systemic inflammation) is the key driver of adiponectin expression in all AT depots and controls its release in the circulation even in the absence of HF syndrome. Values expressed as mean±SEM. ACEi indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCBs, calcium channel blockers; DM, diabetes mellitus; EF, ejection fraction; HF, heart failure; and hsCRP, high-sensitivity C-reactive protein.
*Values expressed as median (25th-75th percentile). †P<0.001; ‡P<0.01 vs healthy controls.
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Given that classic inflammatory biomarkers (circulating hsCRP and IL-6) were not significant predictors of circulating adiponectin, we quantified the local expression of ADIPOQ gene in the human AT biopsies where we observed that circulating IL-6 was inversely related with the ADIPOQ gene expression ( Figure 3D Figure 3G-3I ). Importantly, the correlation between PPAR-γ and ADIPOQ gene expression was significantly stronger in Fem-AT compared with either Sc-AT (z score, −3.846; P=0.00012) or Th-AT (z score, −0.513; P<0.00001). To validate this result biologically, we used the expression of CD36 as the positive control, as CD36 expression is known to be regulated predominantly by PPAR-γ, and we demonstrated that the correlation between PPAR-γ and CD36 gene was similar across all AT depot types ( Figure 3J -3L).
To explain the regional variability in the responsiveness of human AT to systemic low-grade inflammation, we performed immunohistochemistry of Th-AT, Sc-AT, and Fem-AT sections from 7 consecutive patients, and we observed significantly lower infiltration of Fem-AT by CD68 + cells (macrophages) compared with Sc-AT (intermediate infiltration) and Th-AT (highest infiltration) as demonstrated in Figure 4B and 4J to 4L. This was also confirmed by quantifying CD68 mRNA levels in all three AT depots in the population included in study arm 2, where there was a 3-fold difference in CD68 gene expression in Th-AT compared with Fem-AT and a 2-fold difference between Sc-AT and Fem-AT ( Figure 4A ). Interestingly, the Circulating adiponectin levels and underlying cardiovascular disease status. A, In the cross-sectional cohort of patients with coronary artery disease (CAD)/heart failure (HF), there was a significant inverse association between body mass index (BMI) and circulating adiponectin (AdN) levels among the healthy individuals (n=201). This association was weaker but still significant in patients with CAD with normal ejection fraction (EF>50%, n=173) or mildly impaired left ventricular EF (EF=35-50%, n=135, B) and was lost among patients with HF and severely impaired EF (<35%) in the presence (n=33) or absence (n=33) of CAD (C). D, Circulating adiponectin was similar between healthy individuals and patients with CAD and without HF (normal or mildly impaired EF). However, patients with HF (EF<35%) had a striking elevation of circulating adiponectin in the presence or absence of CAD. E, Circulating adiponectin was significantly correlated with flowmediated dilatation (FMD) of the brachial artery in healthy individuals (n=162). F, This association was weaker in patients with CAD and preserved or mildly/moderately impaired left ventricular systolic function (defined by EF>50% [n=158] or 35-50% [n=90], respectively), in the subpopulations of study arm 1. G, This association was lost in patients with ischemic (n=30) or nonischemic (n=32) HF. H, In patients with CAD without HF undergoing coronary artery bypass grafting (CABG) surgery (population in study arm 2), the association between circulating adiponectin and FMD was also weak but still significant. There were no significant associations between circulating adiponectin and endotheliumindependent dilatation of the brachial artery in any of the study populations (data not shown). Pearson correlation coefficients are presented when a significant correlation was identified (A-C, E-H). Figure 4C and 4G-4I). We then assessed macrophages' M1/M2 polarization in the various AT depots. In the population of study arm 2, we quantified gene expression of CCR7 (C-C chemokine receptor type 7 or CD107, marker of M1 macrophages) and CD206 (mannose receptor C type 1 or CD206, marker of M2 macrophages). 21 The CCR7/ CD206 gene expression ratio in Th-AT was ≈3-fold higher than Sc-AT and ≈5-fold higher than Fem-AT ( Figure 4D ). By using immunohistochemistry, we then stained AT sections for CD40 + (surface marker of M1 macrophages) and CD206 + (surface marker of M2 macrophages), 22 and we observed that the ratio of CD40 + /CD206 + cells in Th-AT was ≈2-fold higher than Sc-AT and ≈5-fold higher than Fem-AT ( Figure 4E and 4M-4R). Interestingly, IL-6-receptor gene expression was significantly lower in Th-AT or Sc-AT compared with Fem-AT ( Figure 4F ). These morphological differences could explain the different responsiveness of Fem-AT depot to exogenous (circulating) inflammatory stimulation in vivo. To further investigate the role of inflammation as a regulator of adiponectin release from human AT in the presence or absence of BNP, we performed an ex vivo study where AT from all three depots (Sc-AT, Th-AT, and Fem-AT) was exposed to IL-6 (25 ng/mL) and tumor necrosis factor-α (4 ng/mL)±BNP (1 nmol/L) for 24 hours. Inflammatory stimulation suppressed the expression of PPAR-γ, CD36, and ADIPOQ gene, resulting into a decrease of adiponectin release in AT culture supernatants only in Fem-AT, an effect that was reversed by BNP ( Figure 5A-5D ). Importantly, none of the other AT depots (Sc-AT or Th-AT) responded to exogenous inflammatory stimulation ( Figure 5A-5D ). This suggested that in human atherosclerosis the higher infiltration of AT depots by macrophages, the more nonresponsive PPAR-γ (and its downstream signaling as described by CD36 and adiponectin) is to the variations of exogenous inflammation (Figures 3-5 ).
Effects of Systemic Inflammation on Adiponectin Levels: Insights From a Clinical Model of Inducible Low-Grade Inflammation
To further investigate the effects of systemic low-grade inflammation on adiponectin levels, we used a clinical model of inducible in vivo inflammation: we randomized 19 healthy young individuals to receive either Salmonella typhi (S.typhi) vaccine (as a means to induce systemic low-grade inflammation) or placebo (normal saline injection) and quantified the changes of circulating adiponectin in parallel to the respective changes of circulating inflammatory markers (IL-6 and hsCRP), at 0, 8, 12, and 24 hours (study arm 4). As we expected from our previously published work on this model, 23 S. typhi vaccination induced a low-grade inflammatory response (Figure 5E-5F ) and significantly reduced serum adiponectin when compared against placebo ( Figure 5G ) independently of any changes in BNP ( Figure 5H ). These findings suggest that systemic low-grade inflammation reduces circulating adiponectin levels in healthy individuals where BNP levels are low, hence biologically nonrelevant.
Discussion
Using a range of ex vivo and in vivo approaches, we explored the mechanisms regulating adiponectin biosynthesis in patients with ischemic heart disease. We demonstrate that plasma BNP is the key determinant of circulating adiponectin and a major driver of adiponectin release from all AT depots of patients with ischemic heart disease. On the contrary, low-grade inflammation observed in CAD is not a significant regulator of circulating adiponectin in this population, as circulating inflammatory biomarkers predict ADIPOQ gene expression and release only in selected AT depots with low infiltration with macrophages (such as femoral AT) but not in highly inflamed depots (ie, thoracic AT). This could also be explained by the stronger effect of PPAR-γ signaling on the regulation of ADIPOQ gene expression in the femoral compared with other fat depots. We then used ex vivo models of human AT and demonstrated that only femoral (but not thoracic or subcutaneous) AT responds to exogenous inflammatory stimulation by suppressing PPAR-γ signaling and adiponectin expression/release, effects reversed by BNP. Induction of systemic low-grade inflammation in healthy individuals by using the model of S. typhi vaccination reduced circulating adiponectin levels when compared with placebo. These findings suggest that circulating adiponectin levels are regulated by complex interactions between cytokines and BNP, and the net effect is determined by the background disease state and the nature of the underlying inflammatory stimulus.
Adiponectin is an adipokine with well-established insulinsensitizing effects, and it is protective against the development of diabetes mellitus. 24 Despite its potential antiatherogenic effects, circulating adiponectin has not been established as a biomarker in CVD because of the conflicting data on its clinical predictive value 1 ; although the first evidence supported that higher adiponectin predicts low CVD risk in healthy individuals, 7 elevated adiponectin levels have been associated with increased mortality in patients with ischemic heart disease. 20 Moreover, in recent meta-analyses, circulating adiponectin has been associated with increased risk for stroke 25 and higher risk for CVD and total mortality in secondary prevention. 26 Importantly, in serial studies by Koh et al, 27, 28 it was clearly demonstrated that conventional treatments (eg, statins or angiotensin-converting enzyme inhibitors and others) routinely used in patients with advanced atherosclerosis may also have a significant impact on circulating adiponectin levels. Therefore, despite the beneficial metabolic effects of adiponectin, its value as a biomarker is poorly understood and the mechanisms regulating its circulating levels are unclear. It is possible that low circulating adiponectin may be detrimental for cardiovascular system in obesity, but in advanced CVD states, its levels are increased as a defense mechanism to protect the cardiovascular system, 29 so in these conditions, it may actually flag the underlying advanced CVD.
Studies with cultured 3T3-L1 cells and human primary adipocytes have consistently shown that proinflammatory cytokines downregulate adiponectin expression and release, 14 whereas in other studies, natriuretic peptides (which are elevated in HF) have the opposite effect. 20 Despite these experimental findings, the net effect of systemic inflammation and BNP on adiponectin biosynthesis in AT of patients with ischemic heart disease is unclear.
In this study, we demonstrate that BNP is a strong stimulus for adiponectin release from all AT depots (both in vivo and ex vivo), controlling circulating adiponectin in patients with coronary atherosclerosis even in the absence of HF. On the contrary, atherosclerosis-associated low-grade inflammation is not related with changes in circulating adiponectin levels in patients with CAD. Circulating IL-6 and hsCRP are inversely related with ADIPOQ gene expression (possibly via PPAR-γ signaling) only in Fem-AT that highly expresses IL-6 receptor but not in more inflamed AT depots, such as Th-AT or Sc-AT, which are highly infiltrated with macrophages shifted toward the M1 (proinflammatory) rather than M2 (resident) phenotype. Our data suggest that endogenous inflammation of Th-AT and Sc-AT may lead to downregulation of IL-6R in these AT depots, reducing their responsiveness to exogenous IL-6 coming from the circulating pool. Importantly, the correlation between circulating adiponectin and endothelial function observed in healthy individuals was weaker in patients with coronary atherosclerosis and was absent in the presence of HF, suggesting that the value of circulating adiponectin as a biomarker in ischemic heart disease is limited by the confounding effect of circulating BNP and the degree of endogenous inflammation within each AT depot, which limits their ability to respond to systemic inflammation by suppressing adiponectin release.
Although acute inflammation in vitro has well-described negative effects on adiponectin biosynthesis in cultured adipocytes, 14 the effects of acute inflammation in vivo are unclear; in mice, lipopolysaccharide injection lowers ADIPOQ gene expression from white AT, 30 but in patients with diabetes mellitus, short-term infusion of IL-6 increases ADIPOQ gene expression in subcutaneous AT. 31 We induced systemic low-grade inflammation in healthy individuals by using S. typhi vaccine, 23 and we observed that this type of inducible inflammation decreased circulating adiponectin levels within 24 hours compared with placebo, having no effects on circulating BNP. This is in agreement with our observation that systemic inflammation suppresses adiponectin biosynthesis in the noninflamed human Fem-AT. This study provides comprehensive evidence that in humans systemic low-grade inflammation suppresses adiponectin levels and identifies its role as potential link between systemic inflammation and the early stages of the development of CVD.
In conclusion, we demonstrate that low-grade inflammation reduces adiponectin levels in populations without significant CVD and low plasma BNP, explaining why its low levels predict the onset of CVD. 7 However, after the development of advanced CVD, adiponectin levels are no longer negatively controlled by low-grade inflammation, but they are driven upward by circulating BNP levels. Therefore, high adiponectin levels in these populations flag the high levels of circulating BNP, explaining why high circulating adiponectin predicts (indirectly) worse clinical outcome in these populations.
Therefore, the interpretation of adiponectin as a biomarker should always take into account the underlying CVD state.
